Seamless ALS Progression Insights

Drive precision in ALS clinical trials with our real-time disease progression forecasts.

Request More Information

Key Benefits

Origent’s flagship predictive analytics engine, purpose-built for neurodegenerative disease modeling, delivered directly to your workflows. Our API integrates our machine learning–based models into your infrastructure—delivering patient-level ALS progression forecasts from baseline clinical data – no extra data entry, no delays. Designed to interface seamlessly with Electronic Data Capture (EDC) platforms, our API provides real-time insights

 

High-Fidelity Predictions Effortless Integration Secure & Compliant
Receive ALSFRS-R and vital capacity forecasts, mortality risks, and time-to-event estimations from validated machine learning models. API-based architecture fits directly into your EDC system with de-identified patient data — no interface needed. Meets ISO 27001 and 21 CFR Part 11 standards, with complete audit trails, encryption, and role-based access.

 

Comprehensive ALS Forecasts, One API Call Away

Origent’s API transforms standardized clinical inputs into a comprehensive suite of predictive endpoints. From functional decline to key disease milestones, each model is trained on multi-center ALS datasets and validated for operational deployment in real-world clinical settings.

 

 

 

How it Works

Origent’s ALS Prediction APIs process standardized ALS clinical data to deliver real-time disease progression insights:

  • Submit de-identified patient visit data via secure HTTPS request
  • API returns structured predictions across 12 ALS outcomes
  • Data integrates into your EDC for analysis, stratification, or trial planning

Comprehensive ALS Forecasts, One API Call Away

Origent’s API transforms standardized clinical inputs into a comprehensive suite of predictive endpoints. From functional decline to key disease milestones, each model is trained on multi-center ALS datasets and validated for operational deployment in real-world clinical settings.

 

ALSFRS-R Score
Loss of Speech
Bulbar function
Wheelchair use
Fine motor function
Feeding tube
Gross motor function
50% Expected Vital Capacity
Respitory function
Survival
Vital Capacity
Time to King’s stage 1 transition
Expected Vital Capacity Percentage
Time to King’s stage 4

Trusted by Leaders in ALS Research

 

From early-phase discovery to post-approval analysis, our predictive tools have supported trial design, enrollment optimization, and regulatory engagement across the ALS drug development pipeline.

 

Massachusetts General Hospital Mitsubishi Tanabe Pharma America

 

Get in Touch

Connect with our team to explore integration options or schedule a live demo.

Request More Information
Share This